CD10 Expression in Urothelial Bladder Carcinomas: A Pilot Study

Abstract

Objectives: The aims of this study were to investigate the expression of CD10 in normal bladder tissue and urothelial bladder carcinomas and to clarify its association with histopathological variables. Materials and Methods: A total of 79 urothelial bladder carcinomas were selected from routine archival material. All cases were reevaluated histopathologically and graded according to the World Health Organization (WHO) 1973, WHO/ISUP 1998, and WHO 1999 systems. The TNM system was used for their pathological staging. CD10 immunohistochemical staining was performed in selected slides. Results: Tumoral cases consisted of 74 men (93.7%) and 5 women (6.3%). According to the pathological stage, 25 (31.6%), 33 (41.8%), and 21 (26.6%) cases had pTa, pT1, and pT2–3 carcinomas, respectively. 34 of 79 (43%) urothelial carcinomas and only 1 of 11 (9.1%) nontumoral cases showed positive CD10 immunostaining. It was a cytoplasmic diffuse or granular immunostaining pattern both in nontumoral and tumoral urothelia. There was no statistically significant difference between tumoral and nontumoral cases with respect to CD10 reactivity (p = 0.051), but there was a trend toward significance. In urothelial tumors, there was a significant inverse correlation between pathological stages and CD10 immunoreactivity (p = 0.036, r = –0,237). There was also a statistically significant difference between pTa and pT2–3 urothelial tumors in relation to the CD10 expression (p = 0.034). No association was detected between CD10 expression and grades according to all systems used (p > 0.05). Conclusions: According to our findings, the CD10 expression in noninvasive carcinomas showed a higher level than that in invasive carcinomas, and it is inversely correlated with the pathological stage. CD10 may play an important role in the progression of urothelial bladder carcinomas, and downregulation probably facilitates invasion, especially muscle invasion.

Histogenesis of Clear Cell Adenocarcinoma in the Urinary Tract: Evidence of Urothelial Origin

“…It is also expressed in several normal and neoplastic tissues (27 -29), including urothelial carcinomas, which show mild to moderate CD10 staining in 43% of cases (27). It is notable that 41% of clear cell adenocarcinomas in our series similarly showed immunoreactivity to antibodies against CD10.…”

“…Hartmann et al (7) described similar genetic changes at chromosomes 4, 8, and 1 in both lesions from a case with multiple recurrences of nephrogenic adenoma and ultimately the development of clear cell adenocarcinoma, but the fact that the two lesions in this patient had different genomic alterations at chromosomes 9 and 17 and the extremely limited case number in this report does not provide a firm evidence to support that these two lesions were causally related to one another. Considering that clear cell adenocarcinoma and urothelial neoplasia have similar expression profiles for AMACR (37) and CD10 (27), it seems reasonable to postulate that clear cell adenocarcinoma arises within urothelium.…”

Psödolipomatozis Koli: Olgu Sunumu

“…Patogenezi kesin olarak bilinmeyen bu antite, mideden rektuma kadar gastrointestinal sistemin değişik bölgelerinde görülebilir 2,3 .…”

“…Lamina propriada belirgin olmak üzere, müskülaris propria ve hatta submukozal alanda da görülebilen, farklı büyüklüklerde boşluklar ile karakterizedir [2][3][4] . Bu boşluklar epitel ile döşeli değildir 3 …”

Immunohistochemical characterization of selected breast lesions

“…With IHC, it can be detected in many hematological malignancies [60][61][62], soft tissue neoplasia (e.g. pleiomorphic undifferentiated sarcoma, fibrosarcomas, leiomyosarcomas and malignant peripheral nerve sheath tumors) [63], as well as in carcinomas of different organs, like the skin [64,65], the lungs [66.], the pancreas [67], the liver [68], the stomach [69], the uterine cervix [70], the kidneys [71], the urinary bladder [72] and the prostate [73]. Such a wide spectrum of expression may 18 suggest a limitation in the usefulness of CD10 immunostaining in routine diagnostic pathology.…”